ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Sanofi Pasteur Inaugurates High Tech Vaccine Production Facility To Respond To Soaring Demand Worldwide
Sanofi Pasteur, the vaccines division of sanofi-aventis
Group, announced today the inauguration of a high-tech vaccine production
facility in France to respond to soaring demand worldwide. This new 100
million euros facility located in Val de Reuil (North West of France)
incorporates the latest technology to produce vaccines that meet the highest
standards of quality. It is part of 600 million euros investments undertaken
by sanofi pasteur in France between 2005 and 2008.
"Sanofi Pasteur's commitment to global health is exemplified
by significant investments in vaccine production infrastructures. These
efforts are aimed at meeting a world demand for vaccines expected to double
by 2016," said Wayne Pisano, President and Chief Executive Officer of sanofi
pasteur, who inaugurated the new production unit. "The new facility will
provide high-end production work environment for dedicated people who produce
vaccines for the world."
The new highly automated facility can produce vaccines against
20 diseases. It is designed to be ready to switch to pandemic influenza
vaccine in the event of a human pandemic influenza, and once a pandemic
influenza strain is identified by the World Health Organization (WHO).
"Sanofi Pasteur Val de Reuil site is a hub for global health
with over two million doses of vaccines shipped worldwide each day. The new
facility will further enable sanofi pasteur to fulfil its commitment of
providing highest quality vaccines to protect people from infectious diseases
wherever they live," added Pisano.
Construction of the 7,800 square-meter building began in 2006.
It is projected to be operational by the end of 2008, upon certification by
health authorities. The facility is scaled to fill 200 million syringes and
vials per year, increasing by two fold the current capacity at this site.
The new filling lines are part of a 200 million euros
investment project in Val de Reuil that also includes a new building
dedicated to vaccine formulation, currently under construction. Formulation,
filling and packaging operations are the last manufacturing steps before
vaccines are shipped to customers under cold chain conditions. Formulation
and filling are performed in a highly automated aseptic environment that
meets the most stringent international good manufacturing practices.
A hub for global health
Sanofi Pasteur Val de Reuil operational site is a hub for
global health: over 700 million doses of vaccines per year shipped worldwide.
Val de Reuil is also the world's largest production site for seasonal
influenza vaccine with 130 million doses produced in 2007.
The Val de Reuil vaccine site was created in 1973 by Institut
Pasteur Production. In 1976, Sanofi - now sanofi-aventis - invested in
Institut Pasteur Production to support its industrial development. Institut
Merieux - now Sanofi Pasteur - acquired Institut Pasteur Production in 1985.
Over one billion Euros invested in five years
Sanofi Pasteur has invested over one billion euros in
industrial capacities worldwide during the last five years (2004-2008) to
meet the growing global demand for vaccines. Key recent investments include
formulation and filling capacities, completion of the world's largest
production unit for inactivated polio vaccine, and a new influenza vaccine
production facility. In 2008, investments translated into the groundbreaking
of a new production building for pediatric vaccines located in Marcy
L'Etoile, near Lyon, France.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company,
discovers, develops and distributes therapeutic solutions to improve the
lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in
New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided
more than a 1.6 billion doses of vaccine in 2007, making it possible to
immunize more than 500 million people across the globe. A world leader in the
vaccine industry, sanofi pasteur offers the broadest range of vaccines
protecting against 20 infectious diseases. The company's heritage, to create
vaccines that protect life, dates back more than a century. Sanofi Pasteur is
the largest company entirely dedicated to vaccines. Every day, the company
invests more than EUR 1 million in research and development. For more
information, please visit: http://www.sanofipasteur.com or
http://www.sanofipasteur.us.
Forward Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include financial projections and estimates and their
underlying assumptions, statements regarding plans, objectives, intentions
and expectations with respect to future events, operations, products and
services, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans" and similar expressions. Although
sanofi-aventis' management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond
the control of sanofi-aventis, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include those discussed or identified in the public filings
with the SEC and the AMF made by sanofi-aventis, including those listed under
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking
Statements" in sanofi-aventis' annual report on Form 20-F for the year ended
December 31, 2007. Other than as required by applicable law, sanofi-aventis
does not undertake any obligation to update or revise any forward-looking
information or statements.
Sanofi Pasteur
Sanofi Pasteur a inaugurat High Tech Vaccin facilitate de productie de a rãspunde la planare Cererea întreaga lume - Sanofi Pasteur Inaugurates High Tech Vaccine Production Facility To Respond To Soaring Demand Worldwide - articole medicale engleza - startsanatate